Bukwang Pharm (003000) - Net Assets

Latest as of September 2025: ₩340.83 Billion KRW ≈ $230.98 Million USD

Based on the latest financial reports, Bukwang Pharm (003000) has net assets worth ₩340.83 Billion KRW (≈ $230.98 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩472.99 Billion ≈ $320.54 Million USD) and total liabilities (₩132.16 Billion ≈ $89.56 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Bukwang Pharm asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩340.83 Billion
% of Total Assets	72.06%
Annual Growth Rate	2.13%
5-Year Change	-9.97%
10-Year Change	8.44%
Growth Volatility	27.82

Bukwang Pharm - Net Assets Trend (2007–2024)

This chart illustrates how Bukwang Pharm's net assets have evolved over time, based on quarterly financial data. Also explore Bukwang Pharm balance sheet assets for the complete picture of this company's asset base.

Annual Net Assets for Bukwang Pharm (2007–2024)

The table below shows the annual net assets of Bukwang Pharm from 2007 to 2024. For live valuation and market cap data, see 003000 stock market capitalisation.

Year	Net Assets	Change
2024-12-31	₩244.15 Billion ≈ $165.45 Million	+4.22%
2023-12-31	₩234.26 Billion ≈ $158.76 Million	-13.82%
2022-12-31	₩271.85 Billion ≈ $184.23 Million	-2.93%
2021-12-31	₩280.06 Billion ≈ $189.79 Million	+3.27%
2020-12-31	₩271.19 Billion ≈ $183.78 Million	-16.94%
2019-12-31	₩326.49 Billion ≈ $221.25 Million	-21.03%
2018-12-31	₩413.44 Billion ≈ $280.18 Million	+95.66%
2017-12-31	₩211.30 Billion ≈ $143.20 Million	-1.55%
2016-12-31	₩214.63 Billion ≈ $145.45 Million	-4.67%
2015-12-31	₩225.15 Billion ≈ $152.58 Million	+7.22%
2014-12-31	₩210.00 Billion ≈ $142.31 Million	+4.44%
2013-12-31	₩201.07 Billion ≈ $136.26 Million	+15.56%
2008-12-31	₩174.01 Billion ≈ $117.92 Million	+1.98%
2007-12-31	₩170.63 Billion ≈ $115.63 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Bukwang Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 16682249305000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	₩166.82 Billion	68.46%
Other Components	₩76.85 Billion	31.54%
Total Equity	₩243.68 Billion	100.00%

Bukwang Pharm Competitors by Market Cap

The table below lists competitors of Bukwang Pharm ranked by their market capitalization.

Company	Market Cap
Shandong Hongyu Agricultural Machinery Co Ltd SHE:002890	$422.59 Million
Caleres Inc NYSE:CAL	$422.68 Million
Goodwill E Health Info Co Ltd SHG:688246	$422.80 Million
Teck Resources Limited F:TPT	$422.91 Million
Norma Group AG NA O.N. XETRA:NOEJ	$422.50 Million
IGG Inc F:I91	$422.37 Million
AS Tallink Grupp HE:TALLINK	$422.35 Million
Lontrue Co Ltd SHE:300175	$422.31 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Bukwang Pharm's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 226,311,356,060 to 243,675,730,040, a change of 17,364,373,980 (7.7%).
Net loss of 2,641,325,690 reduced equity.
Other factors increased equity by 20,005,699,670.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	₩-2.64 Billion	-1.08%
Other Changes	₩20.01 Billion	+8.21%
Total Change	₩-	7.67%

Book Value vs Market Value Analysis

This analysis compares Bukwang Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.93x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	₩3268.34	₩6320.00	x
2018-12-31	₩7324.14	₩6320.00	x
2019-12-31	₩4866.00	₩6320.00	x
2020-12-31	₩4152.55	₩6320.00	x
2021-12-31	₩3938.48	₩6320.00	x
2022-12-31	₩3530.51	₩6320.00	x
2023-12-31	₩3306.00	₩6320.00	x
2024-12-31	₩3268.40	₩6320.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Bukwang Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -1.08%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -1.65%
• Asset Turnover: 0.43x
• Equity Multiplier: 1.53x
Recent ROE (-1.08%) is below the historical average (6.90%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2007	19.75%	21.08%	0.72x	1.29x	₩16.20 Billion
2008	18.18%	19.11%	0.70x	1.36x	₩13.89 Billion
2013	9.71%	14.93%	0.57x	1.13x	₩-575.36 Million
2014	11.25%	16.67%	0.60x	1.13x	₩2.62 Billion
2015	11.17%	17.69%	0.56x	1.13x	₩2.62 Billion
2016	7.36%	11.40%	0.58x	1.11x	₩-5.66 Billion
2017	5.25%	7.36%	0.64x	1.12x	₩-10.04 Billion
2018	35.24%	75.00%	0.39x	1.19x	₩104.33 Billion
2019	-2.27%	-4.41%	0.43x	1.19x	₩-40.04 Billion
2020	-2.79%	-4.25%	0.42x	1.55x	₩-33.05 Billion
2021	-0.34%	-0.50%	0.46x	1.47x	₩-27.88 Billion
2022	-0.94%	-1.30%	0.48x	1.52x	₩-28.80 Billion
2023	-13.84%	-24.88%	0.29x	1.90x	₩-53.96 Billion
2024	-1.08%	-1.65%	0.43x	1.53x	₩-27.01 Billion

Industry Comparison

This section compares Bukwang Pharm's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $401,390,357,055
Average return on equity (ROE) among peers: 0.79%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Bukwang Pharm (003000)	₩340.83 Billion	19.75%	0.39x	$422.58 Million
Dongwha Pharm.Co.Ltd (000020)	$252.93 Billion	10.38%	0.28x	$113.83 Million
Yuhan Corp. (000100)	$407.93 Billion	10.79%	0.55x	$4.57 Billion
Yuhan Corp Preferred (000105)	$1.65 Trillion	2.42%	0.28x	$59.61 Million
Yuyu Pharma (000220)	$69.50 Billion	3.97%	0.28x	$46.55 Million
Yuyu Pharma Inc (000225)	$117.04 Billion	1.10%	0.32x	$17.67 Million
Yuyu Pharma Inc (000227)	$78.29 Billion	7.52%	0.42x	$42.93 Million
Ildong Holdings Co Ltd (000230)	$169.10 Billion	-60.53%	4.10x	$76.14 Million
Samil Pharm (000520)	$127.83 Billion	1.30%	1.90x	$127.90 Million
Donga Socio Holdings (000640)	$875.86 Billion	17.02%	0.60x	$427.15 Million
Jw Pharmac (001060)	$265.44 Billion	13.94%	1.43x	$476.78 Million

About Bukwang Pharm

KO:003000 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$422.58 Million

₩623.56 Billion KRW

Market Cap Rank

#13412 Global

#449 in Korea

Share Price

₩6320.00

Change (1 day)

-3.95%

52-Week Range

₩3225.00 - ₩9600.00

All Time High

₩36947.85